Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, ARS Pharmaceuticals, Inc. reported revenue of $84M, down 5.5% year over year. Operating margin was -212.9% and net margin -203.3%, on a free-cash-flow margin of -203.1% with capital expenditure at 0.4% of revenue. Every figure is computed directly from SPRY's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $84M | -212.9% | -203.3% |
| FY2024 | $89M | -3.5% | 9.0% |
| FY2023 | $0M | -225066.7% | -181216.7% |
| FY2022 | $1M | -2698.8% | -2635.4% |
| FY2021 | $6M | -353.3% | -367.7% |
How does SPRY compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.